“…Toxicity of the CA-based synthetic TAs can be reduced by the longer length of their side chain [7][8][9][10], and as a result of much research efforts, alternative TAs such as octyl-2-CA and n-butyl-CA with a longer side chain have been developed and marketed with commercial brand names, Dermabond® (Johnson & Johnson/Ethicon, Somerville, NJ) and Histoacryl® (B. Braun, Melsungen, Germany), respectively [8][9][10][11]. Recently, pre-polymerization process has been demonstrated to allow allyl 2-CA (PACA) to result in a longer chain structure and better for biocompatibility when tested both in vitro and in vivo [12].…”